A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV.
Carbohydr Polym
; 247: 116740, 2020 Nov 01.
Article
in English
| MEDLINE | ID: covidwho-635683
ABSTRACT
Pulmonary fibrosis (PF) is a lung disease with highly heterogeneous and mortality rate, but its therapeutic options are now still limited. Corona virus disease 2019 (COVID-19) has been characterized by WHO as a pandemic, and the global number of confirmed COVID-19 cases has been more than 8.0 million. It is strongly supported for that PF should be one of the major complications in COVID-19 patients by the evidences of epidemiology, viral immunology and current clinical researches. The anti-PF properties of naturally occurring polysaccharides have attracted increasing attention in last two decades, but is still lack of a comprehensively understanding. In present review, the resources, structural features, anti-PF activities, and underlying mechanisms of these polysaccharides are summarized and analyzed, which was expected to provide a scientific evidence supporting the application of polysaccharides for preventing or treating PF in COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Polysaccharides
/
Pulmonary Fibrosis
/
Biological Products
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Traditional medicine
Limits:
Animals
/
Humans
Language:
English
Journal:
Carbohydr Polym
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS